MS

Morgan Stanley is firing on its fundamentals. FY2025 net income hit a record $16.9B (+25.9% YoY) and diluted EPS reached $10.21 (+28.4%), capping a sharp recovery off the $9.09B trough in FY2023 — the franchise's wealth-management tilt is showing up as a 49.2% net margin and 15.1% ROE, strong for a security broker-dealer. The balance sheet carries $112B of equity against $112B of cash, and management trimmed the share count 1.5% while paying $6.59B in dividends, so capital return is real. The auditor issued an unqualified opinion on both the financials and internal controls, and the 10-K flags no near-term operational threat from climate or its other named risks.

The catch is price, not quality. At $219.86 the stock trades at 21.5x FY2025 EPS — a full multiple for a business whose earnings are inherently cyclical and rate/markets-sensitive, as the swing from $15.0B (FY2021) down to $9.09B (FY2023) and back demonstrates. You are paying a premium-bank multiple at what looks like a cyclical high in profitability; if markets revenue normalizes, the same $10.21 base is not guaranteed to compound. The reported P/S of 10.2x rests on a revenue figure tagged to FY2014 ($34.3B) that is almost certainly stale/mislabeled, so I put no weight on it and anchor valuation on earnings instead.